317 related articles for article (PubMed ID: 36661697)
21. Tumor niche network-defined subtypes predict immunotherapy response of esophageal squamous cell cancer.
Ko KP; Zhang S; Huang Y; Kim B; Zou G; Jun S; Zhang J; Zhao Y; Martin C; Dunbar KJ; Efe G; Rustgi AK; Nakagawa H; Zhang H; Liu Z; Park JI
iScience; 2024 May; 27(5):109795. PubMed ID: 38741711
[TBL] [Abstract][Full Text] [Related]
22. Understanding Esophageal Cancer: The Challenges and Opportunities for the Next Decade.
Yang J; Liu X; Cao S; Dong X; Rao S; Cai K
Front Oncol; 2020; 10():1727. PubMed ID: 33014854
[TBL] [Abstract][Full Text] [Related]
23. Esophageal cancer: the rise of adenocarcinoma over squamous cell carcinoma in the Asian belt.
Grille VJ; Campbell S; Gibbs JF; Bauer TL
J Gastrointest Oncol; 2021 Jul; 12(Suppl 2):S339-S349. PubMed ID: 34422398
[TBL] [Abstract][Full Text] [Related]
24. Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma.
Ooki A; Osumi H; Chin K; Watanabe M; Yamaguchi K
Ther Adv Med Oncol; 2023; 15():17588359221138377. PubMed ID: 36872946
[TBL] [Abstract][Full Text] [Related]
25. Tracking the evolution of esophageal squamous cell carcinoma under dynamic immune selection by multi-omics sequencing.
Cui S; McGranahan N; Gao J; Chen P; Jiang W; Yang L; Ma L; Liao J; Xie T; Xie C; Enver T; Wu S
Nat Commun; 2023 Feb; 14(1):892. PubMed ID: 36807354
[TBL] [Abstract][Full Text] [Related]
26. Radiotherapy combined with immune checkpoint inhibitors in locally advanced/metastatic esophageal squamous cell carcinoma: clinical trials, efficacy and future directions.
Jiang M; Hu Y; Lin G; Chen C; Li H
Front Immunol; 2023; 14():1177085. PubMed ID: 37325652
[TBL] [Abstract][Full Text] [Related]
27. Immune evasion in esophageal squamous cell cancer: From the perspective of tumor microenvironment.
Li R; Huang B; Tian H; Sun Z
Front Oncol; 2022; 12():1096717. PubMed ID: 36698392
[TBL] [Abstract][Full Text] [Related]
28. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial.
Yin J; Yuan J; Li Y; Fang Y; Wang R; Jiao H; Tang H; Zhang S; Lin S; Su F; Gu J; Jiang T; Lin D; Huang Z; Du C; Wu K; Tan L; Zhou Q
Nat Med; 2023 Aug; 29(8):2068-2078. PubMed ID: 37488287
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of immunochemotherapy, immunotherapy, chemotherapy, and targeted therapy as first-line treatment for advanced and metastatic esophageal cancer: a systematic review and network meta-analysis.
Gao Z; Huang S; Wang S; Tang D; Xu W; Zeng R; Qiao G
Lancet Reg Health West Pac; 2023 Sep; 38():100841. PubMed ID: 37457900
[TBL] [Abstract][Full Text] [Related]
30. A fibroblast-associated signature predicts prognosis and immunotherapy in esophageal squamous cell cancer.
Ren Q; Zhang P; Zhang X; Feng Y; Li L; Lin H; Yu Y
Front Immunol; 2023; 14():1199040. PubMed ID: 37313409
[TBL] [Abstract][Full Text] [Related]
31. The efficacy and safety of neoadjuvant immunotherapy in resectable locally advanced esophageal squamous cell carcinoma: A systematic review and meta-analysis.
He W; Wang C; Li C; Nie X; Li H; Li J; Zhao N; Chen H; Miao X; Han Y; Peng L; Leng X
Front Immunol; 2023; 14():1118902. PubMed ID: 36875107
[TBL] [Abstract][Full Text] [Related]
32. Profile of Nivolumab in the Treatment of Resected Esophageal Squamous Cell Carcinoma: A Review of the Clinical Data.
Kim Y; Yamamoto S; Kato K
Cancer Manag Res; 2023; 15():399-406. PubMed ID: 37197006
[TBL] [Abstract][Full Text] [Related]
33. Single-cell transcriptomic analysis deciphers key transitional signatures associated with oncogenic evolution in human intramucosal oesophageal squamous cell carcinoma.
Liu XY; Liu YB; Xu JC; Zhang YF; Ruan YY; Zhao Y; Wu LF; Hu JW; Zhang Z; He MJ; Chen TY; Xu XY; Zhang JW; Zhang YQ; Zhou PH
Clin Transl Med; 2023 Mar; 13(3):e1203. PubMed ID: 36855810
[TBL] [Abstract][Full Text] [Related]
34. First-line serplulimab or placebo plus chemotherapy in PD-L1-positive esophageal squamous cell carcinoma: a randomized, double-blind phase 3 trial.
Song Y; Zhang B; Xin D; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Li J; Wang Q; Zhu J; Huang J;
Nat Med; 2023 Feb; 29(2):473-482. PubMed ID: 36732627
[TBL] [Abstract][Full Text] [Related]
35. Combining Solid and Liquid Biopsy for Therapy Monitoring in Esophageal Cancer.
Richter F; Henssen C; Steiert TA; Meissner T; Mehdorn AS; Röcken C; Franke A; Egberts JH; Becker T; Sebens S; Forster M
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445849
[TBL] [Abstract][Full Text] [Related]
36. Harnessing the abscopal effect for gastrointestinal malignancies in the era of immunotherapy.
Hino C; Lee EW; Yang GY
J Gastrointest Oncol; 2023 Jun; 14(3):1613-1625. PubMed ID: 37435204
[TBL] [Abstract][Full Text] [Related]
37. The possible molecular mechanism underlying the involvement of the variable shear factor QKI in the epithelial-mesenchymal transformation of oesophageal cancer.
Cui Y; Wu Y; Zhu Y; Liu W; Huang L; Hong Z; Zhang M; Zheng X; Sun G
PLoS One; 2023; 18(7):e0288403. PubMed ID: 37428781
[TBL] [Abstract][Full Text] [Related]
38. Perioperative therapy landscape for locally advanced, resectable esophageal cancer: an updated literature review.
Mukherji R; Alqahtani A; Yin C; Caso R; Noel MS; Khaitan PG
J Thorac Dis; 2023 Jun; 15(6):3466-3487. PubMed ID: 37426147
[TBL] [Abstract][Full Text] [Related]
39. The transcriptional landscape and diagnostic potential of long non-coding RNAs in esophageal squamous cell carcinoma.
Zhou M; Bao S; Gong T; Wang Q; Sun J; Li J; Lu M; Sun W; Su J; Chen H; Liu Z
Nat Commun; 2023 Jun; 14(1):3799. PubMed ID: 37365153
[TBL] [Abstract][Full Text] [Related]
40. The genomic signature of resistance to platinum-containing neoadjuvant therapy based on single-cell data.
Sui Q; Hu Z; Jin X; Bian Y; Liang J; Zhang H; Yang H; Lin Z; Wang Q; Zhan C; Chen Z
Cell Biosci; 2023 Jun; 13(1):103. PubMed ID: 37291676
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
